SAB BIOTHERAPEUTICS, INC. Earnings Per Share, Basic and Diluted
SAB BIOTHERAPEUTICS, INC. (SABS) reported Earnings Per Share, Basic and Diluted of -$0.63 per share for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-29.
Discontinued › Income Statement › Earnings Per Share
us-gaap:EarningsPerShareBasicAndDiluted · last filed 2022-03-29
- SAB BIOTHERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-09-30 was -$0.02.
- SAB BIOTHERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-06-30 was -$0.15.
- SAB BIOTHERAPEUTICS, INC. earnings per share, basic and diluted for the quarter ending 2021-03-31 was $0.23.
- SAB BIOTHERAPEUTICS, INC. earnings per share, basic and diluted for fiscal 2021 was -$0.63.
| Period end | Earnings Per Share, Basic and Diluted 2 month | Earnings Per Share, Basic and Diluted 3 month | Earnings Per Share, Basic and Diluted 3 month as first filed | Earnings Per Share, Basic and Diluted 6 month | Earnings Per Share, Basic and Diluted 6 month as first filed | Earnings Per Share, Basic and Diluted 9 month | Earnings Per Share, Basic and Diluted 12 month |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | -$0.63 10-K · filed 2022-03-29 | ||||||
| 2021-09-30 | -$0.02 10-Q · filed 2021-11-22 | -$0.47 derived: net income ÷ weighted average shares · filed 2022-11-14 | $0.03 10-Q · filed 2021-11-22 | ||||
| 2021-06-30 | -$0.15 10-Q · filed 2021-11-22 | -$0.50 10-Q · filed 2021-08-09 | $0.06 10-Q · filed 2021-11-22 | $0.18 10-Q · filed 2021-08-09 | |||
| 2021-03-31 | $0.23 10-Q · filed 2021-11-22 | $0.84 10-Q · filed 2021-05-21 | |||||
| 2020-12-31 | $0.00 10-K · filed 2021-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |